SCHEMBL17478016

SCHEMBL17478016

C[C@H]1CN(c2ccc(C(F)(F)F)cc2)C(=O)c2c(I)cnn21

nearest known ligand 0.71

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 20/20 0.71
KCNH2 Q12809 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18457880 1.00 GRM2 (0.71) GRM2KCNH2
SCHEMBL17490644 1.00 GRM2 (0.71) GRM2KCNH2
SCHEMBL17490684 0.87 GRM2 (0.72) GRM2KCNH2
SCHEMBL18833304 0.87 GRM2 (0.72) GRM2KCNH2
SCHEMBL22492784 0.86 GRM2 (0.71) GRM2KCNH2
SCHEMBL16397720 0.86 GRM2 (0.53) GRM2KCNH2
SCHEMBL25859202 0.86 GRM2 (0.53) GRM2KCNH2
SCHEMBL17485550 0.85 GRM2 (0.62) GRM2KCNH2
SCHEMBL17490641 0.85 GRM2 (0.53) GRM2KCNH2
SCHEMBL17490642 0.85 GRM2 (0.53) GRM2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12150941-B2 Process for preparing substituted pyrazolo[1,5-a]pyrazines Sumitomo Pharma Co., Ltd. (JP) 2024-11-26 US disclosed
EP-3719023-B1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF SUMITOMO PHARMA CO LTD (JP) 2024-10-16 EP disclosed
US-20230210850-A1 PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES Sumitomo Pharma Co., Ltd. (JP) 2023-07-06 US disclosed
US-20230210850-A1 PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES Sumitomo Pharma Co., Ltd. (JP) 2023-07-06 US disclosed
CN-111601811-B 6, 7-dihydropyrazolo [1,5-a ] pyrazinone derivatives and medical uses thereof 住友制药株式会社 2023-05-05 CN disclosed
US-11633395-B2 Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor Sumitomo Pharma Co., Ltd. (JP) 2023-04-25 US disclosed
US-20210177995-A1 RADIOLABELLED mGluR2 PET LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2021-06-17 US disclosed
US-11033641-B2 Radiolabelled mGluR2/3 pet ligands JANSSEN PHARMACEUTICA NV (BE) 2021-06-15 US disclosed
US-10967078-B2 Radiolabelled mGluR2 PET ligands JANSSEN PHARMACEUTICA NV (BE) 2021-04-06 US disclosed
US-10953008-B2 Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-03-23 US disclosed
US-20160115169-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2016-04-28 US disclosed
US-20160115169-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2016-04-28 US disclosed
US-20160115169-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2016-04-28 US disclosed
WO-2016016380-A1 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2016-02-04 WO disclosed
WO-2016016395-A1 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2016-02-04 WO disclosed
WO-2016016383-A1 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2016-02-04 WO disclosed
WO-2016016383-A1 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2016-02-04 WO disclosed
WO-2016016382-A1 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2016-02-04 WO disclosed
WO-2016016382-A1 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2016-02-04 WO disclosed
WO-2016016381-A1 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210850-A1 PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES CYP3A5, CYP2F1, CYP4Z1 GRM2 3682/4885KCNH2 275/4885
US-12150941-B2 Process for preparing substituted pyrazolo[1,5-a]pyrazines CYP3A5, CYP2F1, CYP4Z1 GRM2 3682/4885KCNH2 275/4885
US-10953008-B2 Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor GRM5, GRM1, GRM2 GRM2 3/4885KCNH2 880/4885
US-10967078-B2 Radiolabelled mGluR2 PET ligands GRM2, GRM3, GRM1 GRM2 1/4885KCNH2 1222/4885
US-20160115169-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS GRM2, GRM5, GRM1 GRM2 1/4885KCNH2 1222/4885
US-11033641-B2 Radiolabelled mGluR2/3 pet ligands GRM3, GRM2, GRM5 GRM2 2/4885KCNH2 1368/4885
US-11633395-B2 Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor GRM5, GRM1, GRM2 GRM2 3/4885KCNH2 880/4885
US-20210177995-A1 RADIOLABELLED mGluR2 PET LIGANDS GRM2, GRM3, GRM1 GRM2 1/4885KCNH2 1222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.